Align Technology, Inc. (NASDAQ:ALGN) Shares Acquired by Natixis Advisors LLC

Natixis Advisors LLC boosted its stake in shares of Align Technology, Inc. (NASDAQ:ALGN - Free Report) by 21.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,654 shares of the medical equipment provider's stock after buying an additional 3,344 shares during the period. Natixis Advisors LLC's holdings in Align Technology were worth $4,744,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. lifted its holdings in Align Technology by 854.5% in the second quarter. Cullen Frost Bankers Inc. now owns 105 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 94 shares during the last quarter. Innealta Capital LLC purchased a new stake in Align Technology in the second quarter valued at $26,000. Rothschild Investment LLC acquired a new position in shares of Align Technology in the 2nd quarter valued at $26,000. Versant Capital Management Inc grew its holdings in shares of Align Technology by 547.1% during the 2nd quarter. Versant Capital Management Inc now owns 110 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 93 shares during the period. Finally, LRI Investments LLC acquired a new stake in shares of Align Technology during the 1st quarter worth about $29,000. 88.43% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on ALGN shares. Robert W. Baird decreased their target price on shares of Align Technology from $325.00 to $276.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Piper Sandler lowered their price objective on shares of Align Technology from $285.00 to $275.00 and set an "overweight" rating for the company in a research report on Thursday, October 24th. Stifel Nicolaus dropped their target price on shares of Align Technology from $285.00 to $275.00 and set a "buy" rating for the company in a report on Thursday, October 24th. Needham & Company LLC restated a "hold" rating on shares of Align Technology in a research note on Monday, November 4th. Finally, Morgan Stanley dropped their price objective on Align Technology from $310.00 to $280.00 and set an "overweight" rating for the company in a research note on Thursday, October 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $276.38.

Align Technology Trading Down 1.0 %

NASDAQ:ALGN opened at $225.89 on Friday. The stock has a fifty day moving average price of $228.54 and a 200 day moving average price of $238.16. Align Technology, Inc. has a 12-month low of $196.09 and a 12-month high of $335.40. The firm has a market cap of $16.86 billion, a PE ratio of 38.55, a price-to-earnings-growth ratio of 5.91 and a beta of 1.65.

Align Technology (NASDAQ:ALGN - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $2.35 EPS for the quarter, topping analysts' consensus estimates of $2.31 by $0.04. Align Technology had a return on equity of 13.99% and a net margin of 11.15%. The business had revenue of $977.87 million during the quarter, compared to the consensus estimate of $990.05 million. During the same period in the previous year, the company posted $1.62 earnings per share. The business's revenue for the quarter was up 1.8% on a year-over-year basis. Equities analysts forecast that Align Technology, Inc. will post 7.45 EPS for the current year.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.